Pegcetacoplan：PNH补体抑制的新机遇。

IF 2.1 Q3 HEMATOLOGY

Journal of Blood Medicine Pub Date : 2023-03-29 eCollection Date: 2023-01-01 DOI:10.2147/JBM.S362220

Ilene Ceil Weitz

{"title":"Pegcetacoplan：PNH补体抑制的新机遇。","authors":"Ilene Ceil Weitz","doi":"10.2147/JBM.S362220","DOIUrl":null,"url":null,"abstract":"Pegcetacoplan is the newest inhibitor of the complement system to be approved by the FDA and EMA for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The cyclic peptide inhibitor of C3 was evaluated in several clinical trials in PHN leading to its approval. The focus of this paper will review the efficacy and safety of Pegcetacoplan (PEG), and considerations for use in patients with PNH.","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"14 ","pages":"239-245"},"PeriodicalIF":2.1000,"publicationDate":"2023-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/36/4a/jbm-14-239.PMC10066888.pdf","citationCount":"0","resultStr":"{\"title\":\"Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH.\",\"authors\":\"Ilene Ceil Weitz\",\"doi\":\"10.2147/JBM.S362220\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Pegcetacoplan is the newest inhibitor of the complement system to be approved by the FDA and EMA for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The cyclic peptide inhibitor of C3 was evaluated in several clinical trials in PHN leading to its approval. The focus of this paper will review the efficacy and safety of Pegcetacoplan (PEG), and considerations for use in patients with PNH.\",\"PeriodicalId\":15166,\"journal\":{\"name\":\"Journal of Blood Medicine\",\"volume\":\"14 \",\"pages\":\"239-245\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2023-03-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/36/4a/jbm-14-239.PMC10066888.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Blood Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/JBM.S362220\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Blood Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/JBM.S362220","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

Pegcetacoplan 是美国食品药品管理局（FDA）和欧洲药品管理局（EMA）批准用于治疗阵发性夜间血红蛋白尿症（PNH）的最新补体系统抑制剂。这种环肽 C3 抑制剂在几项 PHN 临床试验中进行了评估，最终获得批准。本文将重点回顾 Pegcetacoplan (PEG) 的疗效和安全性，以及用于 PNH 患者的注意事项。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH.

查看原文本刊更多论文

Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH.

Pegcetacoplan is the newest inhibitor of the complement system to be approved by the FDA and EMA for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The cyclic peptide inhibitor of C3 was evaluated in several clinical trials in PHN leading to its approval. The focus of this paper will review the efficacy and safety of Pegcetacoplan (PEG), and considerations for use in patients with PNH.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Blood Medicine HEMATOLOGY-

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

16 weeks

期刊介绍： The Journal of Blood Medicine is an international, peer-reviewed, open access, online journal publishing laboratory, experimental and clinical aspects of all topics pertaining to blood based medicine including but not limited to: Transfusion Medicine (blood components, stem cell transplantation, apheresis, gene based therapeutics), Blood collection, Donor issues, Transmittable diseases, and Blood banking logistics, Immunohematology, Artificial and alternative blood based therapeutics, Hematology including disorders/pathology related to leukocytes/immunology, red cells, platelets and hemostasis, Biotechnology/nanotechnology of blood related medicine, Legal aspects of blood medicine, Historical perspectives. Original research, short reports, reviews, case reports and commentaries are invited.